for people ages 18-80 (full criteria)
at La Jolla, California and other locations
study started
estimated completion:



This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy

Official Title

A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy


Small Fiber Neuropathy VX-150


You can join if…

Open to people ages 18-80

  • Body mass index (BMI) of 18.0 to 31.0 kg/m2, inclusive, and a total body weight >50 kg
  • Diagnosis of small fiber neuropathy, as per European Federation Neurological Societies(EFNS)/American Academy of Neurology (AAN) guidelines, with pain for at least 3 months prior to screening
  • Reduction below the 5th percentile of sex and age-adjusted normal values in epidermal nerve fiber density on punch skin biopsy at the distal site of the leg performed at screening
  • Normal nerve conduction studies (NCS), including presence of sural response.
  • Average NRS score between ≥4 and ≤9 reported in the daily diary on Days -7 through -1

You CAN'T join if...

  • History in the past 10 years of malignancy except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ
  • History of connective tissue disorders, sarcoidosis, Sjögren's syndrome, amyloidosis,Fabry's disease, celiac disease, lyme disease, autoimmune disorders
  • A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses
  • Current clinically significant liver or kidney dysfunction
  • Current uncontrolled thyroid dysfunction
  • A diagnosis of diabetes, HbA1C ≥8% at screening
  • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
  • Concomitant severe pain conditions which may impair self-assessment of pain due to small fiber neuropathy

Other protocol defined Inclusion/Exclusion criteria may apply.


  • University of California San Diego
    La Jolla California 92093 United States
  • SDS Clinical Trials, Inc.
    Orange California 92868 United States


in progress, not accepting new patients
Start Date
Completion Date
Vertex Pharmaceuticals Incorporated
Phase 2
Study Type
Last Updated